Onclive Team

Coping with challenges is part of the human condition, but self-awareness can have far-reaching results. Just ask Edith A. Perez, MD, about her experience attending medical school.

Alternative payment methods in cancer care are front and center in a Medicare initiative to have 85% of all fee-for-service payments tied to quality or value by 2016, and 90% by 2018.

Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non–small cell lung cancer (NSCLC), following their initial debut in 2012.

Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.

Almost half of patients with borderline resectable or locally advanced pancreatic cancer had objective responses to treatment with an investigational chemokine receptor antagonist.

Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR), data from a retrospective study reported at the 2015 Gastrointestinal Cancers Symposium showed.

Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.

With a March 31 deadline looming for the 114th Congress to either patch or repeal the sustainable growth rate (SGR) formula, the Health Subcommittee of the US House of Representatives' Energy and Commerce Committee will hold a hearing to discuss the future of the fundamentally flawed formula used to set Medicare physician payments.

OncLive® and Stephenson Cancer Center, the only comprehensive academic cancer center in Oklahoma, have become partners in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced.

Hagop M. Kantarjian, MD, has built the nation's largest clinical leukemia practice, in part to ensure that leukemia studies are completed efficiently and in a timely manner.

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

A lung cancer researcher who has served on the editorial boards of major medical journals, Howard L. "Jack" West, MD, has made communicating with oncology specialists and patients a part of his professional mission.

Newer drugs for patients with relapsed and refractory Hodgkin lymphoma

Rituximab dose should be based on age and sex.

Only 10% of current medical students aspire to open up shop as a solo practitioner-a 50% drop since 2008. Last year, 17% of students surveyed said that solo practice was a consideration. On the other hand, those students who anticipate seeking employment with a large group practice or hospital has risen to 73%, as compared with 70% last year.

When Vincent T. DeVita Jr, MD, began testing a cocktail of four chemotherapies against advanced Hodgkin disease back in 1964, the disease was uniformly fatal.

Treatment with the TKI sorafenib in combination with standard chemotherapy increased event-free survival by 11.3 months compared with standard chemotherapy plus placebo in patients with newly diagnosed acute myeloid leukemia.

A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk

Older patients with moderate- or high-risk breast cancer had a similar disease-free survival with the bisphosphonate therapy ibandronate alone or in combination with capecitabine.

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was two and a half, shares the challenging and painful experiences of battling the disease.

Some patients with heavily treated acute myelogenous leukemia benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199).

Ninety-six percent of patients with relapsed or refractory Hodgkin lymphoma who received treatment with the combination of brentuximab vedotin and bendamustine responded to treatment without experiencing dose-limiting toxicity.

Almost 90% of patients with relapsed or refractory mantle cell lymphoma responded to the targeted combination of ibrutinib and rituximab.

Treatment with carfilzomib in combination with lenalidomide and dexamethasone increased PFS by 8.7 months in patients with relapsed multiple myeloma when compared with lenalidomide and dexamethasone alone.

At least 80% of patients with B-precursor acute lymphoblastic leukemia had a complete minimal residual disease response after a single cycle of treatment with the CD19-directed antibody blinatumomab.

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

Steven Rosenberg always knew that he wanted to become a physician scientist, and he quickly advanced to become the chief of surgery at the National Cancer Institute (NCI) at just 34 years of age.

ASCO members who need hands-on assistance in practice management, quality care assessment and improvement, and efficiency and business intelligence will be able to contact a soon to be established clinical affairs department at the organization.

A growing understanding of follicular lymphoma pathogenesis is resulting in new drug candidates and approaches to clinical treatment.

As new therapies enter the treatment landscape for metastatic disease, the role of the oncology nurse becomes even more critical in educating patients about what side effects to look out for and the importance of reporting any adverse events promptly.